Cancer Genetics, Inc. (CGIX) just came public on April 10, 2013 and raised roughly $62 million through two stock offerings. The company's primary objective is to be a leader in development and commercialization of proprietary genomic tests and services. Given their recent equity offerings, the company is now in a great position to implement their growth strategy. Management has set reasonable growth targets for their business, which could generate substantial revenue growth over the next several years, I believe revenues could grow from the current $7M FY2013 to over $50M by FY2015 and earnings could approach $0.90 to $1.00. I believe the stock could approach $30 by sometime in 2015.
Alan Mertz, president of the American Clinical Laboratory...
Only subscribers can access this article, which is part of the PRO research library covering 3,612 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: